Effective October 1, 2020, the board of directors of Akouos, Inc. appointed Sachiyo Minegishi as the company’s Treasurer and Assistant Secretary. Upon commencement of her appointment, Ms. Minegishi assumed the duties of the company’s principal financial officer and principal accounting officer and Emmanuel Simons, the company’s Chief Executive Officer, ceased to serve as principal financial officer and principal accounting officer. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Ms. Minegishi. Ms. Minegishi served from April 2016 to September 2020 in various roles of increasing responsibility at bluebird bio, Inc., including, most recently, as vice president, global program lead for sickle cell disease (SCD) and previously as vice president, global brand lead, SCD and oncology portfolio. From September 2012 to April 2016, Ms. Minegishi served in various roles at Aegerion Pharmaceuticals Inc., including as senior director, U.S. cardiology rare disease marketing and as senior director, global business development. Effective October 1, 2020, the Board promoted Jennifer Wellman to the Company’s Chief Operating Officer. Ms. Wellman has over 20 years of experience in adeno-associated viral (AAV) vector gene therapy research and development, and previously served as senior vice president of regulatory and quality of the Company from March 2018 to September 2020. In 2018, Ms. Wellman also served as a part-time consultant for various biotechnology companies. From October 2013 to August 2017, Ms. Wellman was co-founder and head of product development strategy and head of regulatory strategy at Spark Therapeutics, Inc.